$ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Healthcare
Sector
Biotechnology
Industry
Arnon Rosenthal
CEO
175
Employees
$1.56
Current Price
$204.11M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 4 | $228,224.50 | 115,760 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 4 | $228,224.50 | 115,760 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 5 | $233,047.50 | 117,580 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Rosenthal Arnon Director | Sale | 87,216 | $1.97 | $172,190.55 | View Details |
| Jun 3, 2026 | Wong-Sarad Grace Principal Accounting Officer | Sale | 3,475 | $1.88 | $6,542.73 | View Details |
| Jun 2, 2026 | Wong-Sarad Grace Principal Accounting Officer | Sale | 5,709 | $1.97 | $11,270.71 | View Details |
| Jun 2, 2026 | Berkley Neil Lindsay CFO & Chief Business Officer | Sale | 19,360 | $1.97 | $38,220.51 | View Details |
| Apr 16, 2026 | Wong-Sarad Grace Principal Accounting Officer | Sale | 1,820 | $2.65 | $4,823.00 | View Details |
15 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history